Loading...
•
Sep 30, 2021
Day One Q3 2021 Earnings Report
Announced third quarter 2021 financial results and corporate progress.
Key Takeaways
Day One Biopharmaceuticals reported a net loss of $19.2 million for the third quarter of 2021. The company's cash and cash equivalents totaled $297.2 million as of September 30, 2021, which is expected to fund operations into the second half of 2023.
FIREFLY-1, a pivotal Phase 2 clinical trial of DAY101 in pediatric low-grade glioma (pLGG), continues active enrollment; initial data are expected in the first half of 2022.
Day One will present a poster at the 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting on November 12, 2021, highlighting single agent activity of DAY101 in Spindle Cell Carcinoma.
Day One is also conducting a Phase 2 monotherapy trial of DAY101 in adult patients with recurrent, progressive, or refractory solid tumors harboring MAPK pathway aberrations.
Day One strengthened its leadership team with appointment of Jaa Roberson as chief people officer and expanded its board of directors with the appointment of Scott Garland.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...